The fourth annual BRDS on genome editing and silencing for precision medicines

Amit Kumar Chaudhary, Rajan Sharma Bhattarai, Ram I Mahato

Research output: Contribution to journalArticle

Abstract

Precision medicine is promising for treating human diseases, as it focuses on tailoring drugs to a patient’s genes, environment, and lifestyle. The need for personalized medicines has opened the doors for turning nucleic acids into therapeutics. Although gene therapy has the potential to treat and cure genetic and acquired diseases, it needs to overcome certain obstacles before creating the overall prescription drugs. Recent advancement in the life science has helped to understand the effective manipulation and delivery of genome-engineering tools better. The use of sequence-specific nucleases allows genetic changes in human cells to be easily made with higher efficiency and precision than before. Nanotechnology has made rapid advancement in the field of drug delivery, but the delivery of nucleic acids presents unique challenges. Also, designing efficient and short time-consuming genome-editing tools with negligible off-target effects are in high demand for precision medicine. In the fourth annual Biopharmaceutical Research and Development Symposium (BRDS) held at the University of Nebraska Medical Center (UNMC) on September 7–8, 2017, we covered different facets of developing tools for precision medicine for therapeutic and diagnosis of genetic disorders.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalDrug Delivery and Translational Research
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Precision Medicine
Inborn Genetic Diseases
Research
Nucleic Acids
Nanotechnology
Prescription Drugs
Biological Science Disciplines
Pharmaceutical Preparations
Genetic Therapy
Life Style
Genome
Gene Editing
Therapeutics
Genes

Keywords

  • Drug delivery
  • Genome-editing
  • Immunotherapy
  • Nanomedicines
  • Precision medicine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

The fourth annual BRDS on genome editing and silencing for precision medicines. / Chaudhary, Amit Kumar; Bhattarai, Rajan Sharma; Mahato, Ram I.

In: Drug Delivery and Translational Research, Vol. 8, No. 1, 01.02.2018, p. 266-272.

Research output: Contribution to journalArticle

Chaudhary, Amit Kumar ; Bhattarai, Rajan Sharma ; Mahato, Ram I. / The fourth annual BRDS on genome editing and silencing for precision medicines. In: Drug Delivery and Translational Research. 2018 ; Vol. 8, No. 1. pp. 266-272.
@article{9091e2f808434f469bcfc9173138caf6,
title = "The fourth annual BRDS on genome editing and silencing for precision medicines",
abstract = "Precision medicine is promising for treating human diseases, as it focuses on tailoring drugs to a patient’s genes, environment, and lifestyle. The need for personalized medicines has opened the doors for turning nucleic acids into therapeutics. Although gene therapy has the potential to treat and cure genetic and acquired diseases, it needs to overcome certain obstacles before creating the overall prescription drugs. Recent advancement in the life science has helped to understand the effective manipulation and delivery of genome-engineering tools better. The use of sequence-specific nucleases allows genetic changes in human cells to be easily made with higher efficiency and precision than before. Nanotechnology has made rapid advancement in the field of drug delivery, but the delivery of nucleic acids presents unique challenges. Also, designing efficient and short time-consuming genome-editing tools with negligible off-target effects are in high demand for precision medicine. In the fourth annual Biopharmaceutical Research and Development Symposium (BRDS) held at the University of Nebraska Medical Center (UNMC) on September 7–8, 2017, we covered different facets of developing tools for precision medicine for therapeutic and diagnosis of genetic disorders.",
keywords = "Drug delivery, Genome-editing, Immunotherapy, Nanomedicines, Precision medicine",
author = "Chaudhary, {Amit Kumar} and Bhattarai, {Rajan Sharma} and Mahato, {Ram I}",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s13346-017-0457-5",
language = "English (US)",
volume = "8",
pages = "266--272",
journal = "Drug Delivery and Translational Research",
issn = "2190-393X",
publisher = "Springer Publishing Company",
number = "1",

}

TY - JOUR

T1 - The fourth annual BRDS on genome editing and silencing for precision medicines

AU - Chaudhary, Amit Kumar

AU - Bhattarai, Rajan Sharma

AU - Mahato, Ram I

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Precision medicine is promising for treating human diseases, as it focuses on tailoring drugs to a patient’s genes, environment, and lifestyle. The need for personalized medicines has opened the doors for turning nucleic acids into therapeutics. Although gene therapy has the potential to treat and cure genetic and acquired diseases, it needs to overcome certain obstacles before creating the overall prescription drugs. Recent advancement in the life science has helped to understand the effective manipulation and delivery of genome-engineering tools better. The use of sequence-specific nucleases allows genetic changes in human cells to be easily made with higher efficiency and precision than before. Nanotechnology has made rapid advancement in the field of drug delivery, but the delivery of nucleic acids presents unique challenges. Also, designing efficient and short time-consuming genome-editing tools with negligible off-target effects are in high demand for precision medicine. In the fourth annual Biopharmaceutical Research and Development Symposium (BRDS) held at the University of Nebraska Medical Center (UNMC) on September 7–8, 2017, we covered different facets of developing tools for precision medicine for therapeutic and diagnosis of genetic disorders.

AB - Precision medicine is promising for treating human diseases, as it focuses on tailoring drugs to a patient’s genes, environment, and lifestyle. The need for personalized medicines has opened the doors for turning nucleic acids into therapeutics. Although gene therapy has the potential to treat and cure genetic and acquired diseases, it needs to overcome certain obstacles before creating the overall prescription drugs. Recent advancement in the life science has helped to understand the effective manipulation and delivery of genome-engineering tools better. The use of sequence-specific nucleases allows genetic changes in human cells to be easily made with higher efficiency and precision than before. Nanotechnology has made rapid advancement in the field of drug delivery, but the delivery of nucleic acids presents unique challenges. Also, designing efficient and short time-consuming genome-editing tools with negligible off-target effects are in high demand for precision medicine. In the fourth annual Biopharmaceutical Research and Development Symposium (BRDS) held at the University of Nebraska Medical Center (UNMC) on September 7–8, 2017, we covered different facets of developing tools for precision medicine for therapeutic and diagnosis of genetic disorders.

KW - Drug delivery

KW - Genome-editing

KW - Immunotherapy

KW - Nanomedicines

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85040042300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040042300&partnerID=8YFLogxK

U2 - 10.1007/s13346-017-0457-5

DO - 10.1007/s13346-017-0457-5

M3 - Article

VL - 8

SP - 266

EP - 272

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

SN - 2190-393X

IS - 1

ER -